CIRS will attend In-cosmetics Global 2026 in Paris, providing cosmetic regulatory compliance, market access, and efficacy testing services at Stand 2D59.

In March 2026, the Shanghai Municipal, Fujian Provincial, Hubei Provincial, and Anhui Provincial Medical Products Administrations successively issued announcements regarding cosmetic supervision and sampling inspections. A total of 12 batches of products were found to be non-compliant. This summary of the announcements aims to help enterprises stay informed of evolving regulatory trends and strengthen their quality management and compliance awareness.

On March 31, 2026, China’s National Medical Products Administration (NMPA) issued the Announcement on Matters Related to Cosmetic Registration and Filing (Draft for Comments) and is now soliciting public comments.

On March 30, 2026, China's National Medical Products Administration (NMPA) publicly solicited opinions on two mandatory national standards, including “Instructions for use of consumer interest- Part 3: General labelling for cosmetics” and “General requirements of safety and technical for toothpastes”.

Wishing everyone who celebrates a very happy easter! This issue delves into the EU’s PFAS restriction proposal, the U.S. adverse event monitoring system for cosmetics, the potential end of the dual food system for the EU and the UK, and so much more.

CIRS Korea, the Korean office of CIRS Group, participated in CI KOREA 2026 from March 31 to April 3 at KINTEX 2, Korea, where it operated Booth 7B107 and met with a wide range of stakeholders across the cosmetics value chain.

Globally, the regulatory landscape for exosome cosmetics exhibits significant variability. This article systematically reviews the management measures, regulations, and ethical standards concerning exosome cosmetics in various countries/regions, including the United States, the European Union, Japan, South Korea, Taiwan, and mainland China. It explores the context of compliance and prohibitions, as well as their impact on industry development, providing comprehensive global regulatory compliance guidance for cosmetic companies.

On March 25, 2026, the Korea Cosmetic Industry Association (KCIA) issued a notification regarding the Ministry of Food and Drug Safety's (MFDS) issuance of Notification No. 2026-16 to amend the "Regulation on Safety Standards, etc. for Cosmetics." The key amendments include the reorganization of hair dye ingredient lists, the addition of a new UV filter, and the revision of certain test methods. The amendments entered into effect on March 18, 2026.

On March 11, 2026, the U.S. Food and Drug Administration (FDA) launched a new unified platform for analyzing adverse event reports, known as the FDA Adverse Event Monitoring System (AEMS). This initiative marks a significant milestone in the agency’s mission to modernize and enhance transparency regarding the safety of regulated products.On March 11, 2026, the U.S. Food and Drug Administration (FDA) launched a new unified platform for analyzing adverse event reports, known as the FDA Adverse Event Monitoring System (AEMS). This initiative marks a significant milestone in the agency’s mission to modernize and enhance transparency regarding the safety of regulated products.

On March 22, 2026, Delegation from the French laboratory Helioscience and the German raw material supplier Uviva visited CIRS Testing. David Wan, Head of Strategic Development at CIRS Group and Managing Director of CIRS Europe, alongside the CIRS Testing team, warmly welcomed the visitors. The gathering facilitated dynamic discussions regarding emerging industry trends and opportunities for expanded collaboration within the testing sector.